Corcept Therapeutics Inc (CORT)
21.84
+0.20
(+0.95%)
USD |
NASDAQ |
Mar 28, 16:00
21.84
0.00 (0.00%)
After-Hours: 16:24
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.357B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -9.72% |
| Valuation | |
| PE Ratio | 24.82 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 6.299 |
| Price to Book Value | 4.697 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 61.65% |
News
Headline
Wire
Time (ET)
Yahoo
03/27 08:42
Canaccord Genuity Adjusts Price Target on Corcept Therapeutics to $32 From $33, Maintains Buy Rating
MT Newswires
03/08 10:21
MT Newswires
03/06 12:07
Globe Newswire
03/06 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/05/2023* | 17:00 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/05/2023* | -- | Results | Q1 2023 | -- | 0.23 | -- | |
| 02/28/2023 | 17:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/28/2023 | -- | Results | Q4 2022 | 0.14 | 0.28 | -49.40% | |
| 11/03/2022 | 17:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/03/2022 | -- | Results | Q3 2022 | 0.30 | 0.28 | 7.14% | |
| 08/03/2022 | 17:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/03/2022 | -- | Results | Q2 2022 | 0.24 | 0.28 | -15.29% |
*Estimated Date/Time
Earnings
Profile
Edit
| Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. |
| URL | https://www.corcept.com |
| Investor Relations URL | https://ir.corcept.com/investor-relations |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Feb. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 27, 2023.
Fundamentals
| Revenue (TTM) | 401.86M |
| Total Expenses (TTM) | 289.22M |
| Net Income (TTM) | 101.42M |
| Total Assets (Quarterly) | 583.43M |
| Total Liabilities (Quarterly) | 81.59M |
| Shareholders Equity (Quarterly) | 501.84M |
| Cash from Operations (TTM) | 120.32M |
| Cash from Investing (TTM) | -114.33M |
| Cash from Financing (TTM) | -17.28M |
Ratings
Profile
Edit
| Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. |
| URL | https://www.corcept.com |
| Investor Relations URL | https://ir.corcept.com/investor-relations |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Feb. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| PJP | 10.60M USD | 3.51% |
| F00001F6GN | 281178.0 USD | 2.81% |
| TGFRX | 421038.0 USD | 2.72% |
| F00001EYP6 | 257399.0 USD | 2.57% |
| F00001E1JP | 254162.0 USD | 2.54% |
| PSCH | 6.150M USD | 2.13% |
| SBIO | 1.548M USD | 1.64% |
| KAUCX | 64.32M USD | 1.32% |
| JSMD | 1.821M USD | 1.00% |
| ASQCX | 1.331M USD | 0.88% |
| IHE | 3.084M USD | 0.84% |
| GSSC | 1.295M USD | 0.30% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| CORT Tweets |